 Amryt Pharma PLC NASDAQ:AMYT; AIM:AMYT was granted a priority review of its new drug application for Oleogel-S10 by the US Food Drug Administration with a decision expected on or before November 30. The watchdogs fast-track has shortened the regulatory timeline from 10 months to six. 